CBD, CBN, and THC: What a New Narrative Review Says About Psychiatric Risk and Benefit
CBD CBN THC psychiatric effects were compared in a new narrative review spanning PubMed, Scopus, and Web of Science through March 2026. CBD showed preclinical promise but unproven clinical benefit, and CBN evidence remained too thin for any…
Cannabis & Psychosis Study
This cannabis psychosis study examined whether cannabis and tobacco co-use predicted psychosis conversion in people already considered clinically high risk. The paper identified a concerning subgroup signal involving heavy cannabis use and light tobacco…
Exploring Histamine Brain Pathways in Psychiatric Disorders
This study on histamine brain pathways psychiatric disorders maps histamine-related genes across the human brain and their relation to cognition, emotion, and sleep. Findings suggest histamine plays a broad role in brain organization linked to…
High-Potency Cannabis: America’s New Pastime and Psychiatry’s Next Challenge
High-potency THC products dominate the US cannabis market, posing new challenges for psychiatry. These products require updated dosing guidelines and harm reduction strategies. Understanding high-potency THC products is essential for clinical assessment…
The Madness of Using Cannabis to Treat Mental Health | The Spectator Australia
Cannabis mental health skepticism reflects ongoing debate about its use in psychiatry. Understanding the evidence is crucial for clinical guidelines and patient safety. This skepticism influences access and prescribing practices.